Fig. 1.

 Discounted mean quality-adjusted life-years (QALYs) per person and costs per person for the screening strategies in the base case. The strategies using gFOBT (guaiac-based fecal occult blood testing), FIT (fecal immunochemical testing), and/or COLO (colonoscopy) were all more effective and less costly than no screening. Among the ^mSEPT9 (methylated Septin 9 DNA)-based strategies, ^mSEPT9-3well q2 (3-well assay every 2 years) was more effective and less costly than no screening, while ^mSEPT9-3well q1 (3-well assay every year), ^mSEPT9-2well q2 (2-well assay every 2 years), and ^mSEPT9-2well q1 (2-well assay every year) were all highly cost-effective but not cost-saving.